Prevalence of metabolically associated steatotic liver disease in the elderly: analysis and perspectives

   Metabolically associated steatotic liver disease (MASLD) is becoming a major public health problem, especially among the elderly. The recent change in nomenclature from “nonalcoholic fatty liver disease” to “MASLD” reflects a more accurate understanding of the pathogenesis of the disease, linking it to metabolic disorders such as insulin resistance, obesity, and metabolic syndrome. This new terminology emphasizes the importance of a comprehensive approach to the diagnosis and treatment of the disease, given its close association with metabolic disorders and cardiovascular risk. Current estimates suggest that 24 % of the adult population, i. e. one billion people worldwide, suffer from the disease. Interestingly, the prevalence of fatty liver disease peaks between the ages of 40–50 years in men and 60–69 years in women, and then declines slightly in older age groups (over 70 years). The prevalence of MASLD is increasing worldwide, reflecting the increasing incidence of obesity, type 2 diabetes mellitus, and metabolic syndrome. The elderly are particularly susceptible to MASLD due to age-related metabolic changes, comorbidities. Aging is associated with changes in lipid metabolism, insulin resistance, and increased fat mass, which predispose the elderly to hepatic lipid accumulation and subsequent liver damage. In addition, age-related decline in the liver»s regenerative capacity may exacerbate the progression of hepatic steatosis to advanced stages such as steatohepatitis and hepatic fibrosis. However, MASLD in the elderly remains under-recognized and under-diagnosed, posing challenges for timely intervention and treatment. Prospects for addressing MASLD in the elderly emphasize the importance of comprehensive geriatric assessment, including evaluation of metabolic health and liver function.

1. Eslam M., Newsome P.N., Sarin S.K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202–9. DOI: 10.1016/j.jhep.2020.03.039

2. Lim S., Kim J.W., Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2021;32(7):500–14. DOI: 10.1016/j.tem.2021.04.008

3. Maev I.V., Kucheryavy Yu.A, Andreev D.N. The liver and biliary tract in the metabolic syndrome : a manual for physicians. Moscow, 2020. (In Russ.).

4. Younossi Z.M., Golabi P., de Avila L. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes : a systematic review and meta-analysis. J Hepatol 2019;71(4):793–801. DOI: 10.1016/j.jhep.2019.06.021

5. Kaya E., Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol 2022;10(2):329–38. DOI: 10.14218/JCTH.2021.00178

6. WHO. Ageing and health. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/ageing-and-health

7. Huang S.C., Su H.J., Kao J.H. et al. Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease. Gut Liver 2021;15(3):451–8. DOI: 10.5009/gnl20218

8. Rinella M.E., Lazarus J.V., Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 2024;29(1):101133. DOI: 10.1016/j.aohep.2023.101133

9. Jones K., Timchenko L., Timchenko N.A. The role of CUGBP1 in age-dependent changes of liver functions. Ageing Res Rev 2012;11(4):442–9. DOI: 10.1016/j.arr.2012.02.007

10. Frith J., Day C.P., Henderson E. et al. Non-alcoholic fatty liver disease in older people. Gerontology 2009;55(6):607–13. DOI: 10.1159/000235677

11. Anantharaju A., Feller A., Chedid A. Aging liver. A review. Gerontology 2002;48(6):343–53. DOI: 10.1159/000065506

12. Jin J., Wang G.L., Timchenko L., Timchenko N.A. GSK3beta and aging liver. Aging (Albany NY) 2009;1(6):582–5. DOI: 10.18632/aging.100060

13. Singh P., Goode T., Dean A. et al. Elevated interferon gamma signaling contributes to impaired regeneration in the aged liver. J Gerontol A Biol Sci Med Sci 2011;66(9):944–56. DOI: 10.1093/gerona/glr094

14. Zhang C., Cuervo A.M. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med 2008;14(9):959–65. DOI: 10.1038/nm.1851

15. Mallikarjuna K., Shanmugam K.R., Nishanth K. et al. Alcohol-induced deterioration in primary antioxidant and glutathione family enzymes reversed by exercise training in the liver of old rats. Alcohol 2010;44(6):523–9. DOI: 10.1016/j.alcohol.2010.07.004

16. Riazi K., Azhari H., Charette J.H. et al. The prevalence and incidence of NAFLD worldwide : a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022;7(9):851–61. DOI: 10.1016/S2468-1253(22)00165-0

17. Golabi P., Paik J., Reddy R. et al. Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. BMC Gastroenterol 2019;19(1):56. DOI: 10.1186/s12876-019-0972-6

18. Eguchi Y., Hyogo H., Ono M. et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012;47(5):586–95. DOI: 10.1007/s00535-012-0533-z

19. Younossi Z.M., Koenig A.B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84. DOI: 10.1002/hep.28431

20. Miyaaki H., Ichikawa T., Nakao K. et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int 2008;28(4):519–24. DOI: 10.1111/j.1478-3231.2007.01614.x

21. Huang Y.P., Zhang S., Zhang M. et al. Gender-specific prevalence of metabolic-associated fatty liver disease among government employees in Tianjin, China: a cross-sectional study. BMJ Open 2021;11(12):e056260. DOI: 10.1136/bmjopen-2021-056260

22. Clayton-Chubb D., Kemp W.W., Majeed A. et al. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage. Liver Int 2024;44(1):39–51. DOI: 10.1111/liv.15725

23. Ekusheva E.V. An elderly patient with comorbid pathology in the practice of a cardiologist. RMZh. Meditsinskoe obozrenie = RMJ. Medical Review 2018;2(11):26–9. (In Russ.).

24. Liu J., Ma J., Wang J. et al. Comorbidity analysis according to sex and age in hypertension patients in China. Int J Med Sci 2016;13(2):99–107. DOI: 10.7150/ijms.13456

25. Van den Akker M., Buntinx F., Roos S., Knottnerus J.A. Problems in determining occurrence rates of multimorbidity. J Clin Epidemiol 2001;54(7):675–9. DOI: 10.1016/s0895-4356(00)00358-9

26. Fortin M., Bravo G., Hudon C. et al. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005;3(3):223–8. DOI: 10.1370/afm.272

27. Lazebnik L.B., Konev Yu.V., Drozdov V.N., Efremov L.I. Polypharmacy: geriatric aspect of the problem. Consilium Medicum 2007;9(12):29–34. (In Russ.).

28. Rafiq N., Bai C., Fang Y. et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7(2):234–8. DOI: 10.1016/j.cgh.2008.11.005

29. Simon T.G., Roelstraete B., Khalili H. et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021;70(7):1375–82. DOI: 10.1136/gutjnl-2020-322786

30. Ekstedt M., Hagström H., Nasr P. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61(5):1547–54. DOI: 10.1002/hep.27368

31. Hagström H., Nasr P., Ekstedt M. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017;67(6):1134–6. DOI: 10.1016/j.jhep.2017.07.027

32. Taylor R.S., Taylor R.J., Bayliss S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis. Gastroenterology 2020;158(6):1611–25. DOI: 10.1053/j.gastro.2020.01.043